Nice technology appraisal

NICE's decision on whether a specific medicine should be available on the NHS in England.

Also called: technology appraisal, ta, nice ta, nice approval, nice guidance

Related words clinical trial

Topics Medicines

Questions people ask

What blood tests are used for Crohn's?

NICE's guidance for GPs suggests a full blood count (to look for anaemia and other signs), inflammation markers such as CRP and ESR, kidney and liver tests including albumin, iron, B12, folate and vitamin D levels, and a coeliac test to rule that out. Crohn's & Colitis UK explains that CRP rises with inflammation but can be normal even when the gut is inflamed, so blood tests are used alongside other tests rather than on their own.

Sources

Can I stop my biologic once my Crohn's is in remission?

The 2025 BSG guideline does not suggest routinely stopping advanced therapy, because about a third of people relapse within one to two years of stopping, even after the gut has healed. It says any decision should be made jointly with your IBD team, with close monitoring afterwards. NICE appraisals also ask for regular reviews of whether ongoing treatment is still needed. Never stop a medicine without speaking to your team.

Sources

How can I take part in a Crohn's clinical trial?

The NHS suggests asking your doctor or a patient organisation about trials you may be eligible for. You can also search the NIHR's Be Part of Research website for UK studies and contact research teams directly. Registries such as ISRCTN and ClinicalTrials.gov list studies and their results. Crohn's & Colitis UK explains how new medicines are tested before they are licensed.

Sources

What causes Crohn's disease?

Nobody knows exactly. The NHS and Crohn's & Colitis UK say the immune system goes wrong and attacks the gut. Researchers think it happens in people whose genes make them susceptible, combined with things in the environment and the bacteria living in the gut. NICE's GP summary lists family history, smoking and a recent bout of gastroenteritis as factors linked to a higher risk. NICE describes Crohn's as non-infectious, so it is not something you can catch from someone.

Sources

What is upadacitinib (Rinvoq) and how is it different from biologics?

Upadacitinib is a tablet that belongs to a group called JAK inhibitors. It blocks proteins inside cells that switch on the immune response, rather than being an antibody given by drip or injection. Trials found it worked better than placebo for moderate to severe Crohn's, and NICE recommends it after a biologic has failed or when anti-TNFs are unsuitable. Shingles was more common in people taking it.

Sources

Where to read more

Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

NICE Guideline Jul 2017 For professionals

NICE's appraisal recommending ustekinumab (Stelara) for adults with moderate to severe Crohn's disease when standard treatment or an anti-TNF medicine has not worked, stopped working or cannot be used. It says the choice between biologics should be made with the patient, using the cheapest suitable option.

Topics Biologics and newer medicines Medicines

Jargon explained interleukin inhibitor TNF-alpha inhibitor biological therapy

Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)

NICE Guideline Aug 2015 For professionals

NICE's appraisal recommending vedolizumab (Entyvio) for adults with moderate to severe Crohn's disease when an anti-TNF medicine has failed, stopped working or is unsuitable. It is given as a planned course and reassessed at 12 months.

Topics Biologics and newer medicines Medicines

Jargon explained anti-TNF TNF-alpha inhibitor patient access scheme moderately to severely active

Guselkumab for previously treated moderately to severely active Crohn's disease (TA1095)

NICE Guideline Aug 2025 For professionals

NICE's appraisal allowing guselkumab (Tremfya) for adults with moderate to severe Crohn's disease when earlier treatment has not worked or cannot be tolerated and an anti-TNF medicine is not working or unsuitable. It asks clinicians to choose the least expensive of the suitable options, which include guselkumab, risankizumab and vedolizumab.

Topics Biologics and newer medicines Medicines

Jargon explained IL-23 inhibitor TNF-alpha inhibitor conventional treatment

Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (HTG401, formerly DG22)

NICE Guideline Feb 2016 For professionals

NICE guidance on laboratory test kits that measure how much infliximab or adalimumab is in the blood and whether the body has made antibodies against the drug. The guidance was first published as diagnostics guidance 22 and has been moved into NICE's HealthTech programme without changing its content.

Topics Monitoring Biologics and newer medicines

Jargon explained therapeutic drug monitoring drug level anti-drug antibodies ELISA anti-TNF

Infliximab and adalimumab for the treatment of Crohn's disease (TA187)

NICE Guideline May 2010 For professionals

NICE's appraisal approving infliximab and adalimumab on the NHS for adults with severe active Crohn's disease when standard treatments such as steroids or immunosuppressants have not worked or cannot be used. It applies to biosimilar versions too, and says treatment should be reviewed at least every 12 months to decide whether to continue.

Topics Biologics and newer medicines Medicines

Jargon explained anti-TNF biosimilar conventional therapy severe active Crohn's disease

SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea (HTG598)

NICE Guideline Nov 2021 For professionals

NICE's current guidance on the SeHCAT scan, which replaced its 2012 guidance (DG7). NICE says there is not yet enough evidence to recommend SeHCAT for routine use, including for people with Crohn's who have not had part of the ileum removed and have long-lasting diarrhoea, but hospitals already using it can carry on while collecting more data.

Topics Diagnosis and tests Toilet habits

Jargon explained SeHCAT bile acid diarrhoea ileal resection

Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (HTG320, formerly DG11)

NICE Guideline Oct 2013 For professionals

NICE's recommendation that a faecal calprotectin poo test can be used to help doctors tell IBD apart from IBS. For adults with recent lower gut symptoms it applies when cancer is not suspected and proper quality checks and local pathways are in place; it is also recommended for children with suspected IBD who have been referred to a specialist. This guidance was first published as DG11 and NICE has since renumbered it HTG320 without changing it.

Topics Diagnosis and tests

Jargon explained faecal calprotectin inflammatory bowel disease irritable bowel syndrome

Crohn's disease (Clinical Knowledge Summary)

NICE CKS Guide May 2024 For professionals

NICE's summary for GPs on Crohn's, describing it as a long-term, relapsing and remitting inflammatory condition of the gut that is not an infection. It is organised into when to suspect Crohn's, which tests to arrange, what else it might be, and how to manage suspected and confirmed cases in primary care.

Topics About Crohn's disease Diagnosis and tests Flare-ups Complications

Jargon explained relapsing-remitting inflammation primary care inflammatory bowel disease flare-up

Search everything for "nice technology appraisal"